News & Investors

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Jun 23, 2017
STAMFORD, Conn., June 23, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the U.S. Food and Drug Administration (FDA) h...
Jun 21, 2017
- Trial will continue to test two doses of CR845 and aims to enroll up to 450 patients - - Both doses of CR845 well tolerated - - Trial completion expected in the fourth quarter of 2017 - STAMFORD, Conn., June 21, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commerci...
May 17, 2017
Dr. Joseph Stauffer to deliver opening remarks and discuss kappa opioid receptor agonists as a novel approach to acute and chronic pain managementDr. Stauffer serves as co-chair and on the event's Scientific Advisory Board STAMFORD, Conn., May 17, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on ...
May 12, 2017
STAMFORD, Conn., May 12, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a key opinion leader (KOL) b...
May 4, 2017
- Reported statistically significant positive top-line results from Part A of Phase 2/3 trial for I.V. CR845 in chronic kidney disease (CKD)-associated pruritus -  - Completed public offering of common stock, raising net proceeds of $86.5 million - - Conference call today at 4:30 p.m. ET -STAMFORD, Conn., May 04, 2017 (GLOBE NEWSWIRE) -- Cara ...
Apr 27, 2017
STAMFORD, Conn., April 27, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live...
Apr 24, 2017
STAMFORD, Conn., April 24, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced summary results from its Phase 1 safety trial sho...
Apr 5, 2017
STAMFORD, Conn., April 05, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the closing of its underwritten public offering of 5,...
Mar 30, 2017
STAMFORD, Conn., March 30, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the pricing of its underwritten public offering of 4,...
Mar 29, 2017
STAMFORD, Conn., March 29, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has commenced an underwritten public offering...
Mar 28, 2017
STAMFORD, Conn., March 28, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will pres...
Mar 28, 2017
Met primary endpoint with 68% reduction in worst itching scores versus placebo after eight-week treatment period (p...
Mar 13, 2017
STAMFORD, Conn., March 13, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it will present at two upcoming medical meetings...
Mar 9, 2017
STAMFORD, Conn., March 09, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced financial results for the fourth quarter and full year ended Dec...
Mar 2, 2017
STAMFORD, Conn., March 02, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live...
Nov 29, 2016
- Part A of the trial will evaluate three doses of I.V. CR845 versus placebo in 160 dialysis patients   -- Top-line data expected in first quarter of 2017  - STAMFORD, Conn., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities design...
Nov 22, 2016
STAMFORD, Conn., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will parti...
Nov 8, 2016
STAMFORD, Conn., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will prese...
Nov 3, 2016
-  Currently enrolling three late stage studies with CR845 totaling over 900 patients  -   -  Top line data expected in 1H 2017  - -  Conference call today at 4:30 p.m. ET  - STAMFORD, CONN., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemi...
Oct 31, 2016
STAMFORD, Conn., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the presentation of two posters at Kidney Week 2016, t...
Oct 27, 2016
STAMFORD, Conn., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live ...
Oct 12, 2016
STAMFORD, Conn., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced its participation at two upcoming medical meetings, bo...
Oct 3, 2016
Webcast to be held Thursday, October 6, 2016 at 11:00 a.m. ET STAMFORD, Conn., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today a...
Sep 29, 2016
STAMFORD, Conn., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it will host an industry symposium titled "Movin...
Sep 15, 2016
Trial to evaluate three tablet strengths of CR845 versus placebo in approximately 330 osteoarthritis patients Top-line data expected in first half of 2017 STAMFORD, Conn., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed...
Sep 2, 2016
STAMFORD, Conn., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will pres...
Sep 1, 2016
Pain experts to discuss developments in kappa opioid receptor agonists and the future of pain managementCompany to present data from Phase 2 chronic osteoarthritis pain and human abuse liability trials of CR845 in poster sessions STAMFORD, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company fo...
Aug 5, 2016
STAMFORD, Conn., Aug. 05, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will prese...
Aug 4, 2016
- Resumed patient enrollment in adaptive pivotal trial of I.V. CR845 in post-operative pain - - Initiated adaptive Phase 2/3 trial for I.V. CR845 in dialysis patients with uremic pruritus - - Initiation of Phase 2b trial of Oral CR845 in osteoarthritis patients expected in Q3, 2016 - - Conference call today at 4:30 p.m. ET - STAMFORD, Conn....
Jul 28, 2016
STAMFORD, Conn., July 28, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live ...
Jul 13, 2016
STAMFORD, Conn., July 13, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that its preclinical data will be presented in a poste...
Jul 5, 2016
STAMFORD, Conn., July 05, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will prese...
Jun 29, 2016
STAMFORD, Conn., June 29, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has initiated patient recruitment for an adapt...
Jun 9, 2016
STAMFORD, Conn., June 09, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the presentation of preclinical data, including one la...
Jun 6, 2016
STAMFORD, Conn., June 06, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has resumed patient recruitment after the U.S....
May 31, 2016
Leading experts to discuss unique pharmacology of peripherally selective opioids to manage chronic and acute pain during opening session Company to present positive data from Phase 2a study of Oral CR845 in chronic pain patients STAMFORD, Conn., May 31, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focu...
May 5, 2016
- Conference call today at 4:30 p.m. ET - SHELTON, Conn., May 05, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today ann...
May 4, 2016
Pain experts to discuss kappa opioid receptor agonists as alternative to standard mu opioid agonistsSHELTON, Conn., May 04, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting periphe...
Apr 28, 2016
SHELTON, Conn., April 28, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the Company will host a conference call and live audio webca...
Apr 20, 2016
SHELTON, Conn., April 20, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has received notice from the U.S. Food and ...
Apr 5, 2016
SHELTON, Conn., April 05, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a com...
Mar 10, 2016
SHELTON, Conn., March 10, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced financial results for the fourth quarter and fu...
Mar 3, 2016
SHELTON, Conn., March 03, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, wil...
Mar 3, 2016
SHELTON, Conn., March 03, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the Company will host a conference call and live audio webca...
Feb 25, 2016
Limited number of asymptomatic, transient rises in serum sodium triggers pre-specified safety review and protocol clinical holdNo CR845-associated serious adverse events (SAEs) observed to date  Conference call today at 4:30 p.m. ET ...
Feb 18, 2016
Symposium to highlight latest developments in kappa opioid receptor agonists, the future of pain management Positive data from human abuse liability study of I.V. CR845 to be presented in poster sessions SHELTON, Conn., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Cara Therapeut...
Dec 9, 2015
Dose-related reduction observed in mean baseline pain score up to 34 percent after two weeks, with statistically significant reduction in mean rescue medication for top 5.0 mg dose All four tablet strengths observed to be safe and well tolerated Establishes therapeutic doses and dosing regimen for Phase 2b trial in 2016 ...
Dec 1, 2015
SHELTON, Conn., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that its Head of Clinical Development, Paul Tiseo, Ph.D., will presen...
Nov 25, 2015
SHELTON, Conn., Nov. 25, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present at the Pipe...
Nov 11, 2015
SHELTON, Conn., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company o...
Nov 9, 2015
- Initiated Phase 3 program for I.V. CR845 in acute postoperative pain - - Initiated Phase 2a trial of Oral CR845 in osteoarthritis patients - - Earned $2.75M in milestone payments for clinical development of uremic pruritus - - Conference call today at 4:30 p.m. ET - SHELTON, Conn., Nov. 9, 2015 (GLOBE NEWSWIRE) -- ...
Nov 2, 2015
SHELTON, Conn., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it will host a conference call and live audio webcast on Monday...
Oct 29, 2015
SHELTON, Conn., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that its Chief Medical Officer, Joseph Stauffer, D.O., M.B.A., will ...
Oct 26, 2015
Chief Medical Officer Dr. Joseph Stauffer to discuss potential for kappa opioids SHELTON, Conn., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid re...
Oct 19, 2015
Pain experts to discuss trends in kappa opioid receptor agonists and the future of postoperative pain management Company to present positive data from Phase 2 acute pain trials of I.V. CR845 in poster session SHELTON, Conn., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology c...
Oct 13, 2015
$2.5M Milestones Earned for Advancement of CR845 in Phase 2 Clinical Trials in U.S. and Japan SHELTON, Conn., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting ka...
Sep 28, 2015
SHELTON, Conn., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Chief Medical Officer Joseph Stauffer, D.O., M.B.A., will pres...
Sep 22, 2015
SHELTON, Conn., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it will present a poster at the 8th World Congress on Itch, wh...
Sep 9, 2015
First Pivotal Trial Will Evaluate I.V. CR845, Dosed Pre- and Postoperatively, in Patients Undergoing Abdominal Surgery Top-line data expected in 1H'2016 SHELTON, Conn., Sept. 9, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities desi...
Sep 3, 2015
SHELTON, Conn., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company o...
Sep 1, 2015
Pain Experts to Discuss Developments in Kappa Opioid Receptor Agonists and the Future of Pain Management Company to Present Positive Data From Phase 2 Acute Pain and Human Abuse Liability Trials of CR845 in Poster Sessions SHELTON, Conn., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology ...
Aug 17, 2015
SHELTON, Conn., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the dosing of the first patients in a Phase 2 trial of an oral table...
Aug 10, 2015
Reported statistically-significant positive top-line results from Phase 2 trial for I.V. CR845 in uremic pruritus Completed successful public offering of common stock, raising net proceeds of $75.1 million First Pivotal trial for I.V. CR845 in acute pain on track to begin in 3Q'15 Conference call today at 4:30 p.m. ET ...
Aug 4, 2015
SHELTON, Conn., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the closing of its underwritten public offering of 4,327,956 shar...
Aug 3, 2015
SHELTON, Conn., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 20...
Jul 29, 2015
SHELTON, Conn., July 29, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the pricing of its underwritten public offering of 3,763,440 sha...
Jul 27, 2015
SHELTON, Conn., July 27, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it has commenced an underwritten public offering of shares ...
Jul 23, 2015
Novel peripheral kappa opioid I.V. CR845 achieved statistically-significant results on primary endpoint of reducing worst itch intensity Trial demonstrated statistically significant results on secondary endpoint of quality of life improvements with additional positive trend on itch-related sleep disturbances I.V. CR845 found to be ...
Jun 23, 2015
Top-line data expected in early 3Q'15 SHELTON, Conn., June 23, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced that it has completed enrollment in i...
Jun 10, 2015
SHELTON, Conn., June 10, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it will sponsor a symposium titled "New Analgesic and Abuse Det...
Jun 5, 2015
SHELTON, Conn., June 5, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Chief Medical Officer Dr. Joseph Stauffer will present data from...
May 12, 2015
- End-of-Phase 2 Meeting With FDA Informs Phase 3 Clinical Development Program for Novel Kappa Opioid I.V. CR845 - - Conference Call Today at 4:30 p.m. ET - SHELTON, Conn., May 12, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities d...
May 6, 2015
Pain experts to discuss kappa opioid receptor agonists and latest developments in pain management Company to present positive data from Phase 2, human abuse liability studies of I.V. CR845 during poster sessions SHELTON, Conn., May 6, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focus...
May 5, 2015
SHELTON, Conn., May 5, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on...
Apr 15, 2015
Company to present data from human abuse liability (HAL) study of I.V. CR845  SHELTON, Conn., April 15, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid rece...
Apr 7, 2015
SHELTON, Conn., April 7, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company o...
Mar 26, 2015
- Phase 3 pivotal trials for I.V. CR845 expected to initiate during second quarter of 2015, following scheduled End-of-Phase 2 Meeting - - Reported positive top-line data from human abuse liability trial of I.V. CR845 for the treatment of acute pain - - Reported positive top-line results from Phase 1a/1b trial of tablet formulatio...
Mar 19, 2015
Pain experts to discuss latest kappa opioid agonist data and the future of pain management Company to present positive data from Phase 2 trial of I.V. CR845 during poster sessions SHELTON, Conn., March 19, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commer...
Mar 19, 2015
SHELTON, Conn., March 19, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast...
Mar 13, 2015
SHELTON, Conn., March 13, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a comp...
Feb 10, 2015
SHELTON, Conn., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the issuance of U.S. Patent No. 8,951,970 with claims covering t...
Feb 2, 2015
SHELTON, Conn., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a compan...
Dec 18, 2014
SHELTON, Conn., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The ...
Dec 17, 2014
I.V. CR845 observed to be safe, well tolerated, and to exhibit dose linear exposure in patients undergoing dialysis Effective itch reduction seen in subgroup of patients with uremic pruritus Phase 2 trial in dialysis patients with uremic pruritus underway SHELTON, Conn., Dec. 17, 2014 (GLOBE NEWSWIRE) -- Cara Therape...
Dec 2, 2014
SHELTON, Conn., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the appointment of Joseph Stauffer, D.O., as Chief Medical Office...
Dec 2, 2014
All tested tablet strengths pharmacologically active, safe and well tolerated after single and multiple dose administration Establishes dosing range and regimen for Phase 2 trial design SHELTON, Conn., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and comm...
Nov 25, 2014
SHELTON, Conn., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a compa...
Nov 11, 2014
SHELTON, Conn., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a compa...
Nov 10, 2014
Reported positive top-line data from human abuse liability trial for I.V. CR845 Phase 3 registration trials for I.V. CR845 expected to initiate in early 2015 Conference call today at 4:30 p.m. ET SHELTON, Conn., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company fo...
Nov 3, 2014
SHELTON, Conn., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the Company will host a conference call and live audio webca...
Oct 29, 2014
Trial meets primary endpoint with I.V. CR845 showing highly statistically significant reductions (p ...
Oct 27, 2014
SHELTON, Conn., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the unexpected death of Dr. Robert Medve, the company's Chief Me...
Sep 17, 2014
SHELTON, Conn., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced it is sponsoring and participating in a lunch symposium titled,...
Aug 7, 2014
SHELTON, Conn., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced financial results for the second quarter ended June 30, 2014. ...
Aug 6, 2014
Two-part study to evaluate safety, pharmacokinetics and anti-itch effects in hemodialysis patients Top-line data expected in first half of 2015 SHELTON, Conn., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities desi...
Jul 31, 2014
SHELTON, Conn., July 31, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Thursd...
Jul 31, 2014
Comparator will be pentazocine, a Schedule IV opioid receptor agonist with lower abuse potential than common opioids Top-line data expected in fourth quarter of 2014 SHELTON, Conn., July 31, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new...
Jul 16, 2014
SHELTON, Conn., July 16, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that it has earned a $500,000 milestone payment from Maruishi Pharmaceutical ...
Jun 24, 2014
SHELTON, Conn., June 24, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that Dr. Robert Medve has been named Chief Medical Officer, effective immedia...
Jun 18, 2014
SHELTON, Conn., June 18, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the dosing of the first subjects in a Phase Ia/Ib clinical trial of an oral t...
Jun 2, 2014
SHELTON, Conn., June 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that Eric J. Vandal has been named Vice President, Commercial Operations. Mr. ...
May 12, 2014
SHELTON, Conn., May 12, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced financial results for the first quarter ended March 31, 2014. "The first q...
May 5, 2014
SHELTON, Conn., May 5, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Monday, ...
Apr 2, 2014
SHELTON, Conn., April 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that Dr. Derek Chalmers, President and CEO, will present a company overview a...
Mar 27, 2014
SHELTON, Conn., March 27, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced financial results for the fourth quarter and full year ended December 31, 20...
Mar 20, 2014
SHELTON, Conn., March 20, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Thurs...
Feb 5, 2014
SHELTON, Conn., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the closing of its initial public offering of 5,750,000 shares of common stock...
Jan 31, 2014
SHELTON, Conn., Jan. 31, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public ...
Nov 11, 2013
SHELTON, Conn., Nov. 11, 2013 /PRNewswire/ -- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that it has filed a registration statement on Form S-1 with the U.S. Sec...
Oct 29, 2013
SHELTON, Conn., Oct. 29, 2013 /PRNewswire -- Cara Therapeutics, Inc. today announced top-line results from a Phase 2 clinical trial of its novel, peripherally-acting kappa opioid receptor agonist, I.V. CR845, for the treatment of acute pain following bunionectomy. In a pre-specified analysis for patients who completed the trial ("Completer Analys...
Sep 5, 2013
SHELTON, Conn., September 5, 2013 -- Cara Therapeutics, Inc., a biopharmaceutical company developing novel peripheral analgesics to treat pain and inflammatory conditions, announced today that Derek Chalmers, Chief Executive Officer, will present a company overview at the Stifel 2013 Healthcare Conference on Wednesday, September 11, 2013 at 11:30 a...
Aug 5, 2013
SHELTON, Conn., August 5, 2013 -- Cara Therapeutics, Inc., a biopharmaceutical company developing novel peripheral analgesics to treat pain and inflammatory conditions, announced today that Derek Chalmers, Chief Executive Officer, will present a company overview at the Wedbush Securities Life Sciences Management Access Conference on Wednesday, Augu...
Apr 29, 2013
SHELTON, Conn. and OSAKA, Japan, April 29, 2013 -- Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. (Maruishi) today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara’s lead analgesic drug candidate, CR845, for acute pain and ur...
Jun 11, 2012
PRNewswire -- Cara Therapeutics, Inc. today announced positive results from a Phase II study for the treatment of acute post-operative pain with its novel, peptide-based, peripherally-acting kappa opioid agonist, CR845. The study successfully met its primary endpoint which measured the effect of CR845 treatment on reducing the amount of resc...
May 3, 2012
Cara Therapeutics, Inc. and Chong Kun Dang Pharmaceutical Corporation (CKD Pharm) today announced that they have entered into a licensing agreement that provides CKD Pharm with the exclusive rights to develop and market Cara’s lead analgesic drug candidate, CR845, in the Republic of Korea. Under the terms of the agreement, Cara will receiv...
Apr 3, 2012
SHELTON, Conn., April 3, 2012 — Cara Therapeutics, Inc. today announced the successful completion of a first-in-man Phase I clinical trial of an oral formulation of its peptide-based, peripherally-restricted kappa opioid receptor agonist, CR845. The trial was a single-center, double-blind, placebo-controlled study to evaluate the pharmacok...
Aug 3, 2011
Cara Therapeutics, Inc. today announced the dosing of the first patient in a Phase II clinical trial of its peripherally-selective, kappa opioid agonist, CR845, for the treatment of acute post-operative pain. The double-blind, placebo-controlled trial is expected to enroll a minimum of 200 patients at multiple clinical sites in the United States...
Jul 22, 2010
The $15 million Series D financing Cara Therapeutics Inc. closed this week will go a long way toward advancing the development of its peripherally restricted kappa opioid agonist CR845, said CEO Derek Chalmers... ...
Jul 21, 2010
Shelton, CT, July 21, 2010 /PRNewswire/ — Cara Therapeutics, Inc. announced today that it had closed on a Series D financing of $15 million. The round was led by new investor, Rho Ventures, with participation from previous investors Alta Biopharma, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Healthcare Private Equi...
Feb 22, 2010
San Carlos, CA, Feb 22, 2010 /The Bernstein Report on BioBusiness/ — Cara Therapeutics, Inc. believes its CR845 kappa opioid agonist will fare better than others because the peptide is too large to cross the blood-brain barrier, meaning it should avoid the side effects and narrow therapeutic windows associated with CNS receptor activatio...
Feb 8, 2010
Shelton, CT, Feb 8, 2010 /PRNewswire-FirstCall/ — Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States...
Jan 12, 2009
Shelton, CT, Jan 12, 2009 /PRNewswire-FirstCall/ — Cara Therapeutics, Inc. today announced that it is initiating a Phase II clinical trial of its long-acting peripheral kappa opioid agonist, CR845. The Phase II multi-center, double-blind, placebo-controlled trial will be conducted in the United States and will evaluate the analgesic effica...
Aug 17, 2008
Aug 17, 2008
Aug 17, 2008
Aug 5, 2008
Cara Therapeutics, Inc. today announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of acute and chronic pain. The drug candidate was safe and well-tolerated after intravenous infusion, and resulted in plasma levels of CR845 expected to be ...
Jul 24, 2008
Cara Therapeutics, Inc. announced today that it had closed on $12.3 million of additional funding to its original $24 million Series C financing which was completed in 2007. The round was led by new investor, Devon Park Bioventures, and included participation by Connecticut Innovations. Previous investors participating in the round included; As...
Jul 22, 2008
Cara Therapeutics, Inc. announced today that The United States Patent and Trademark Office has issued U.S. Patent No. 7,402,564 entitled “Synthetic Peptide Amides” under its Accelerated Examination Program. The application was filed on November 12, 2007 and covers Cara’s second generation, peripherally-selective kappa opioid...
Jun 25, 2008
Apr 28, 2008
Cara Therapeutics, Inc. today announced that it has initiated a Phase 1 clinical trial of its long-acting peripheral kappa opioid receptor agonist, CR845. The Phase 1a single-center clinical trial will evaluate the safety, tolerability, pharmacokinetic profile, and pharmacological activity of CR845 in a double-blind, randomized, placebo-controll...
Nov 28, 2006
Cara Therapeutics, Inc. announced today that it had closed on $19 million of its Series C financing. New investors participating in the round include MVM Life Science Partners and Alta Biopharma Partners, as well as previous investors Ascent Biomedical Ventures. In conjunction with the financing, Dr. Stephen Reeders, Managing Partner of MVM Life...
Mar 22, 2006
Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discovery chemistry and informatics products and services, today announced that Tripos Discovery Research Ltd. (TDR), based in Bude, England, has formed a new research collaboration with Cara Therapeutics, an emerging U.S. biotechnology company based in Tarrytown, N.Y. Cara is focused on d...
Jul 28, 2005
Cara Therapeutics, Inc. today announced results of a Phase 1 clinical trial for its peripherally acting kappa opioid agonist, CR665, under development for the treatment of postoperative pain. The drug candidate was safe and well-tolerated after intravenous infusion, and resulted in plasma levels of CR665 expected to be associated with clinical a...
Mar 24, 2005
Cara Therapeutics, Inc. announced today that it had initiated dosing in a Phase 1 clinical trial for CR665, its novel drug candidate for the treatment of postoperative pain. The single-dose protocol is scheduled to be completed in the second quarter of 2005. The study will evaluate the safety, tolerability and pharmacokinetic profile of ...
Page:
1
2
...
9
Next Last
 
= add release to Briefcase